Goldenwell Biotech, Inc. (GWLL)
Oxford Ledge is still expanding full research coverage of GWLL. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Goldenwell Biotech licenses biotech technology to develop freeze-dried peptide and tablet health products, with production planning complete but operations not yet active.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-07-01
- 10-K Annual financial report with audited statements 2026-07-01
- 10-Q/A Amended quarterly report 2026-06-29
- 10-Q/A Amended quarterly report 2026-06-26
- 10-Q/A Amended quarterly report 2026-06-26
Source: SEC EDGAR.
Annual results
5 years of annual figures for GWLL, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $55 | -$296,471 | $0.00 |
| 2024 | $139 | -$131,498 | $0.00 |
| 2023 | — | -$117,361 | $0.00 |
| 2022 | $47,800 | -$985,097 | — |
| 2021 | $15,967 | -$116,981 | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open GWLL in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.